N/A N=30 Investigation of New Intermittent Catheters in Healthy Volunteers
Retention, Urinary
Primary: Residual Urine at 1st Flow-stop — 35.0; 1.1; 0.2; 37.0 mL — p=0.010
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
MALARIA · FEVER · Sweating Fever
Primary: Infection for P. Vivax — 11; 11; 9 days
Phase 4 N=10 Performance of Junctional Tourniquets in Normal Human Volunteers
Hemorrhage
Primary: Effectiveness at Stopping Distal Pulse — 97; 27; 83; 93 percentage of participants
N/A N=120 Clearblue Home Pregnancy Test Consumer Study
Pregnancy
Primary: Consumer Agreement — 100 percentage of agreement
N/A N=18 Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe
Malaria · Plasmodium Falciparum
Primary: Number of Participants Infected — 5; 3; 6 Participants
Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
Early Phase 1 N=6 VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection
Malaria, Vivax
Primary: Number of Participants With Serious Adverse Events — 1 Participants
N/A N=35 Tear Collection in Adult Volunteers
Healthy Volunteers
Primary: Tear Lipid Composition Profile — 39.34; 0.76; 6.58; 1.48 pmole
Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Phase 1 N=8 First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events
N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
Phase 1 N=56 Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
Zika Virus
Primary: Number of Solicited Adverse Events — 1; 0; 0; 0 events
N/A N=20 Wearable Dark-adaptometer in Normal Adult Healthy Volunteers
Photoreceptor Sensitivity Thresholds
Primary: Time to Rod-cone Break (RCB) — 11.34; 9.98 Minutes
Phase 3 N=24,111 Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay
Healthy Donors · HIV Positive
Primary: PRISM HIV O Plus Test Data for Specificity — 10; 15589 participants
N/A N=9 Explorative Clinical Study on the Performance and Acceptance of New Intermittent Catheters in Healthy Volunteers
Compliance, Patient
Primary: Urine Flow Rate — 5.43; 5.47; 2.88 mL per second
Phase 2 N=96 Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Healthy · Pituitary Disease · Thyroid Disease
Primary: TSH Response to TRH — 11.47 mcIU/mL
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
N/A N=159 Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging
Cognition
Primary: Relationship Between Prefrontal Cortex Activation and Respiratory Sinus Arrhythmia — -0.064; 0.00375 Micro mol per second — p=0.008
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
N/A N=18 Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Healthy Volunteer Trial
Optokinetic Nystagmus
Primary: Sensitivity and Specificity of a Computer Algorithm to Detect Artificially Induced Nystagmus — 99.1; 98.6 Percent
N/A N=51 Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients
Anxiety · Healthy Volunteers
Primary: Difference in Learning Rate — 0.009; 0.0058 unitless
N/A N=24 Healthy Adult Volunteer Study of Intraosseous Infusion Using the Sternum
Intraosseous Vascular Access
Primary: Occurrences of Extravasation During Infusion — 2 participants
N/A N=20 Head Stabilization of Healthy Volunteers
Healthy
Primary: Collection of Head Motion Data to be Used in Developing Head Stabilization Methods in Brain Radiation Patients — 95 % of time within tolerance
Phase 1 N=130 COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
Coronavirus
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events — 7; 2; 0; 3 Participants
N/A N=36 SARS-CoV-2 Human Challenge Characterisation Study
Covid19 · SARS-CoV Infection · Corona Virus Infection
Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events
Phase 1 N=12 Aerosol BCG Challenge Study in Historically BCG-vaccinated Volunteers
Tuberculosis
Primary: To Quantify BCG Recoverable From Bronchial Sample — 0; 0; 0; 0 Volunteers with detectable BCG
Phase 1 N=66 Phase 1 Study for IPG11406 in Health Volunteer
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
Phase 4 N=44 Eovist vs. Dotarem Healthy Volunteer MRI
Transient Severe Arterial Phase Motion
Primary: Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath — 28; 38; 35 seconds
Phase 1 N=20 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants
N/A N=5 Proximal Humerus Site for Anesthesia
Intraosseous Vascular Access
Primary: Intraosseous Infusion Flow Rate — 2433.33 mL / hour